vs
Prestige Consumer Healthcare Inc.（PBH）与PREFORMED LINE PRODUCTS CO（PLPC）财务数据对比。点击上方公司名可切换其他公司
Prestige Consumer Healthcare Inc.的季度营收约是PREFORMED LINE PRODUCTS CO的1.6倍（$283.4M vs $173.1M），Prestige Consumer Healthcare Inc.净利率更高（16.5% vs 4.9%，领先11.6%），PREFORMED LINE PRODUCTS CO同比增速更快（3.6% vs -2.4%），Prestige Consumer Healthcare Inc.自由现金流更多（$75.3M vs $11.8M），过去两年PREFORMED LINE PRODUCTS CO的营收复合增速更高（10.8% vs 1.2%）
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
预成型线路产品公司（PLPC）研发、生产和销售适用于输配电、通信及可再生能源基建领域的工程硬件组件，服务全球多地的公用事业、网络运营商及工业客户，提供可提升网络可靠性与运营效率的解决方案。
PBH vs PLPC — 直观对比
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $283.4M | $173.1M |
| 净利润 | $46.7M | $8.4M |
| 毛利率 | 55.5% | 29.8% |
| 营业利润率 | 29.1% | 6.8% |
| 净利率 | 16.5% | 4.9% |
| 营收同比 | -2.4% | 3.6% |
| 净利润同比 | -23.5% | -19.3% |
| 每股收益（稀释后） | $0.97 | $1.72 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $283.4M | $173.1M | ||
| Q3 25 | $274.1M | $178.1M | ||
| Q2 25 | $249.5M | $169.6M | ||
| Q1 25 | $296.5M | $148.5M | ||
| Q4 24 | $290.3M | $167.1M | ||
| Q3 24 | $283.8M | $147.0M | ||
| Q2 24 | $267.1M | $138.7M | ||
| Q1 24 | $277.0M | $140.9M |
| Q4 25 | $46.7M | $8.4M | ||
| Q3 25 | $42.2M | $2.6M | ||
| Q2 25 | $47.5M | $12.7M | ||
| Q1 25 | $50.1M | $11.5M | ||
| Q4 24 | $61.0M | $10.5M | ||
| Q3 24 | $54.4M | $7.7M | ||
| Q2 24 | $49.1M | $9.4M | ||
| Q1 24 | $49.5M | $9.6M |
| Q4 25 | 55.5% | 29.8% | ||
| Q3 25 | 55.3% | 29.7% | ||
| Q2 25 | 56.2% | 32.7% | ||
| Q1 25 | 57.3% | 32.8% | ||
| Q4 24 | 55.5% | 33.3% | ||
| Q3 24 | 55.5% | 31.1% | ||
| Q2 24 | 54.7% | 31.9% | ||
| Q1 24 | 54.8% | 31.3% |
| Q4 25 | 29.1% | 6.8% | ||
| Q3 25 | 29.1% | 7.4% | ||
| Q2 25 | 28.8% | 10.1% | ||
| Q1 25 | 29.8% | 8.8% | ||
| Q4 24 | 31.7% | 10.5% | ||
| Q3 24 | 29.7% | 7.1% | ||
| Q2 24 | 27.0% | 8.1% | ||
| Q1 24 | 29.7% | 8.2% |
| Q4 25 | 16.5% | 4.9% | ||
| Q3 25 | 15.4% | 1.5% | ||
| Q2 25 | 19.0% | 7.5% | ||
| Q1 25 | 16.9% | 7.8% | ||
| Q4 24 | 21.0% | 6.3% | ||
| Q3 24 | 19.2% | 5.2% | ||
| Q2 24 | 18.4% | 6.8% | ||
| Q1 24 | 17.9% | 6.8% |
| Q4 25 | $0.97 | $1.72 | ||
| Q3 25 | $0.86 | $0.53 | ||
| Q2 25 | $0.95 | $2.56 | ||
| Q1 25 | $1.00 | $2.33 | ||
| Q4 24 | $1.22 | $2.13 | ||
| Q3 24 | $1.09 | $1.54 | ||
| Q2 24 | $0.98 | $1.89 | ||
| Q1 24 | $0.98 | $1.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $62.4M | — |
| 总债务越低越好 | $1.0B | $38.3M |
| 股东权益账面价值 | $1.8B | $475.5M |
| 总资产 | $3.5B | $653.6M |
| 负债/权益比越低杠杆越低 | 0.56× | 0.08× |
8季度趋势，按日历期对齐
| Q4 25 | $62.4M | — | ||
| Q3 25 | $119.1M | — | ||
| Q2 25 | $139.5M | — | ||
| Q1 25 | $97.9M | — | ||
| Q4 24 | $50.9M | — | ||
| Q3 24 | $51.5M | — | ||
| Q2 24 | $34.3M | — | ||
| Q1 24 | $46.5M | — |
| Q4 25 | $1.0B | $38.3M | ||
| Q3 25 | $993.1M | $36.0M | ||
| Q2 25 | $992.7M | $31.8M | ||
| Q1 25 | $992.4M | $29.1M | ||
| Q4 24 | $992.0M | $20.8M | ||
| Q3 24 | $1.1B | $27.2M | ||
| Q2 24 | $1.1B | $31.6M | ||
| Q1 24 | $1.1B | $55.0M |
| Q4 25 | $1.8B | $475.5M | ||
| Q3 25 | $1.8B | $466.3M | ||
| Q2 25 | $1.9B | $460.7M | ||
| Q1 25 | $1.8B | $435.8M | ||
| Q4 24 | $1.8B | $422.3M | ||
| Q3 24 | $1.7B | $429.0M | ||
| Q2 24 | $1.7B | $416.2M | ||
| Q1 24 | $1.7B | $413.4M |
| Q4 25 | $3.5B | $653.6M | ||
| Q3 25 | $3.4B | $644.6M | ||
| Q2 25 | $3.4B | $631.5M | ||
| Q1 25 | $3.4B | $592.5M | ||
| Q4 24 | $3.3B | $573.9M | ||
| Q3 24 | $3.3B | $592.0M | ||
| Q2 24 | $3.3B | $572.6M | ||
| Q1 24 | $3.3B | $586.1M |
| Q4 25 | 0.56× | 0.08× | ||
| Q3 25 | 0.54× | 0.08× | ||
| Q2 25 | 0.54× | 0.07× | ||
| Q1 25 | 0.54× | 0.07× | ||
| Q4 24 | 0.55× | 0.05× | ||
| Q3 24 | 0.61× | 0.06× | ||
| Q2 24 | 0.65× | 0.08× | ||
| Q1 24 | 0.68× | 0.13× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $78.3M | $21.9M |
| 自由现金流经营现金流 - 资本支出 | $75.3M | $11.8M |
| 自由现金流率自由现金流/营收 | 26.6% | 6.8% |
| 资本支出强度资本支出/营收 | 1.1% | 5.9% |
| 现金转化率经营现金流/净利润 | 1.68× | 2.60× |
| 过去12个月自由现金流最近4个季度 | $267.2M | $33.3M |
8季度趋势，按日历期对齐
| Q4 25 | $78.3M | $21.9M | ||
| Q3 25 | $57.5M | $18.9M | ||
| Q2 25 | $79.0M | $26.9M | ||
| Q1 25 | $61.8M | $5.7M | ||
| Q4 24 | $65.1M | $24.1M | ||
| Q3 24 | $69.8M | $9.4M | ||
| Q2 24 | $54.8M | $28.3M | ||
| Q1 24 | $66.9M | $5.8M |
| Q4 25 | $75.3M | $11.8M | ||
| Q3 25 | $55.4M | $8.3M | ||
| Q2 25 | $78.2M | $18.6M | ||
| Q1 25 | $58.4M | $-5.3M | ||
| Q4 24 | $63.5M | $20.6M | ||
| Q3 24 | $67.8M | $5.8M | ||
| Q2 24 | $53.6M | $24.6M | ||
| Q1 24 | $63.8M | $1.8M |
| Q4 25 | 26.6% | 6.8% | ||
| Q3 25 | 20.2% | 4.7% | ||
| Q2 25 | 31.3% | 10.9% | ||
| Q1 25 | 19.7% | -3.6% | ||
| Q4 24 | 21.9% | 12.3% | ||
| Q3 24 | 23.9% | 3.9% | ||
| Q2 24 | 20.1% | 17.7% | ||
| Q1 24 | 23.0% | 1.3% |
| Q4 25 | 1.1% | 5.9% | ||
| Q3 25 | 0.8% | 6.0% | ||
| Q2 25 | 0.3% | 4.9% | ||
| Q1 25 | 1.2% | 7.4% | ||
| Q4 24 | 0.5% | 2.1% | ||
| Q3 24 | 0.7% | 2.4% | ||
| Q2 24 | 0.4% | 2.7% | ||
| Q1 24 | 1.1% | 2.8% |
| Q4 25 | 1.68× | 2.60× | ||
| Q3 25 | 1.36× | 7.21× | ||
| Q2 25 | 1.66× | 2.12× | ||
| Q1 25 | 1.23× | 0.49× | ||
| Q4 24 | 1.07× | 2.30× | ||
| Q3 24 | 1.28× | 1.22× | ||
| Q2 24 | 1.12× | 3.02× | ||
| Q1 24 | 1.35× | 0.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
PLPC
暂无分部数据
